240 related articles for article (PubMed ID: 33154553)
1. Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China.
Zhu L; Zhang CY; Li DP; Chen HB; Ma J; Gao H; Ye Y; Wang JY; Fu PP; Lin G
Acta Pharmacol Sin; 2021 Aug; 42(8):1212-1222. PubMed ID: 33154553
[TBL] [Abstract][Full Text] [Related]
2. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.
Lin G; Wang JY; Li N; Li M; Gao H; Ji Y; Zhang F; Wang H; Zhou Y; Ye Y; Xu HX; Zheng J
J Hepatol; 2011 Apr; 54(4):666-73. PubMed ID: 21146894
[TBL] [Abstract][Full Text] [Related]
3. The long persistence of pyrrolizidine alkaloid-derived pyrrole-protein adducts in vivo: Kinetic study following multiple exposures of a pyrrolizidine alkaloid containing extract of Gynura japonica.
Chen Y; Xiong F; Wang W; Jiang K; Ye X; Deng G; Wang C; Yang L; Xiong A; Wang Z
Toxicol Lett; 2020 May; 323():41-47. PubMed ID: 31982501
[TBL] [Abstract][Full Text] [Related]
4. Seneciphylline, a main pyrrolizidine alkaloid in Gynura japonica, induces hepatotoxicity in mice and primary hepatocytes via activating mitochondria-mediated apoptosis.
Wang W; Yang X; Chen Y; Ye X; Jiang K; Xiong A; Yang L; Wang Z
J Appl Toxicol; 2020 Nov; 40(11):1534-1544. PubMed ID: 32618019
[TBL] [Abstract][Full Text] [Related]
5. Blood microRNA Signatures Serve as Potential Diagnostic Biomarkers for Hepatic Sinusoidal Obstruction Syndrome Caused by
Wang X; Zhang W; Yang Y; Chen Y; Zhuge Y; Xiong A; Yang L; Wang Z
Front Pharmacol; 2021; 12():627126. PubMed ID: 33679405
[No Abstract] [Full Text] [Related]
6. Gynura Rhizoma containing pyrrolizidine alkaloids induces the hepatic sinusoidal obstruction syndrome in mice via upregulating fibrosis-related factors.
Zhang F; Zhou Y; Yang X; Xiong AZ; Wang ZT; Yang L
Acta Pharmacol Sin; 2019 Jun; 40(6):781-789. PubMed ID: 30367152
[TBL] [Abstract][Full Text] [Related]
7. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome.
Gao H; Ruan JQ; Chen J; Li N; Ke CQ; Ye Y; Lin G; Wang JY
Drug Des Devel Ther; 2015; 9():4861-8. PubMed ID: 26346783
[TBL] [Abstract][Full Text] [Related]
8. Tusanqi and hepatic sinusoidal obstruction syndrome.
Wang JY; Gao H
J Dig Dis; 2014 Mar; 15(3):105-7. PubMed ID: 24528632
[TBL] [Abstract][Full Text] [Related]
9. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans.
Yang M; Ruan J; Gao H; Li N; Ma J; Xue J; Ye Y; Fu PP; Wang J; Lin G
Arch Toxicol; 2017 Dec; 91(12):3913-3925. PubMed ID: 28620673
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of toxic components in different medicinal parts of Gynura japonica and its toxicity assessment on mice.
Xiong A; Shao Y; Fang L; Yang X; Zhang S; Zheng J; Ding W; Yang L; Wang Z
Phytomedicine; 2019 Feb; 54():77-88. PubMed ID: 30668385
[TBL] [Abstract][Full Text] [Related]
11. Hepatic sinusoidal obstruction syndrome caused by the ingestion of
Cen P; Ding J; Jin J
J Int Med Res; 2021 Apr; 49(4):300060520980649. PubMed ID: 33845617
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome.
Kan X; Ye J; Rong X; Lu Z; Li X; Wang Y; Yang L; Xu K; Song Y; Hou X
Sci Rep; 2016 Nov; 6():37998. PubMed ID: 27897243
[TBL] [Abstract][Full Text] [Related]
13. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.
Yang XQ; Ye J; Li X; Li Q; Song YH
World J Gastroenterol; 2019 Jul; 25(28):3753-3763. PubMed ID: 31391770
[TBL] [Abstract][Full Text] [Related]
14. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Zhuge Y; Liu Y; Xie W; Zou X; Xu J; Wang J;
J Gastroenterol Hepatol; 2019 Apr; 34(4):634-642. PubMed ID: 30669184
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Toxification of 1,2-Unsaturated Pyrrolizidine Alkaloids Causes Human Hepatic Sinusoidal Obstruction Syndrome: The Update.
Teschke R; Vongdala N; Quan NV; Quy TN; Xuan TD
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638760
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study.
Liu F; Rong X; Guo H; Xu D; Liu C; Meng L; Yang X; Guo T; Kan X; Song Y
BMC Gastroenterol; 2020 Feb; 20(1):30. PubMed ID: 32019495
[TBL] [Abstract][Full Text] [Related]
17. Pyrrolizidine Alkaloid-Induced Hepatotoxicity Associated with the Formation of Reactive Metabolite-Derived Pyrrole-Protein Adducts.
Ma J; Li M; Li N; Chan WY; Lin G
Toxins (Basel); 2021 Oct; 13(10):. PubMed ID: 34679016
[TBL] [Abstract][Full Text] [Related]
18. Mass-spectrometry-directed analysis and purification of pyrrolizidine alkaloid cis/trans isomers in Gynura japonica.
Fang L; Xiong A; Yang X; Cheng W; Yang L; Wang Z
J Sep Sci; 2014 Aug; 37(15):2032-8. PubMed ID: 24840731
[TBL] [Abstract][Full Text] [Related]
19. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids.
Gao H; Li N; Wang JY; Zhang SC; Lin G
J Dig Dis; 2012 Jan; 13(1):33-9. PubMed ID: 22188914
[TBL] [Abstract][Full Text] [Related]
20. Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome.
Zhang W; Liu L; Zhang M; Zhang F; Peng C; Zhang B; Chen J; Li L; He J; Xiao J; Feng Y; Wang X; Xiong A; Yang L; Zou X; Yu Y; Zhuge Y
J Clin Transl Hepatol; 2021 Jun; 9(3):345-352. PubMed ID: 34221920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
